THERAPY DOSSIER · th-bb10d820b7f9

Ferrostatin-1, with Fe-citrate(III) as a ferroptosis-promoting comparator

Drug · Ferrostatin-1, a lipophilic radical-trapping ferroptosis inhibitor (tool compound); not returned by ChEMBL name search.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Ferrostatin-1, a lipophilic radical-trapping ferroptosis inhibitor (tool compound); not returned by ChEMBL name search.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32601262 ↗2020Reported benefit

Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1.

MouseIschaemia-reperfusionIntestinal / mesentericC57BL/6J and Nrf2 knockout mice on the same genetic backgroundn = 60 C57BL/6J and 48 Nrf2 knockout mice; n = 6 per group acro…Tail vein injectionFerrostatin-1 1.5 mg/kg; Fe-citrate(III) 15 mg/kg; in vitro…Pre-treatment, prior to blocking the superior mesenteric artery

Model: Intestinal ischaemia-reperfusion induced acute lung injury by clipping the superior mesenteric artery for 45 min followed by 180 min reperfusion

Ferrostatin-1 pre-treatment ameliorated lung pathological injury, pulmonary oedema, lipid peroxidation and cell death whereas iron aggravated them, and Nrf2 inhibited ferroptosis by promoting SLC7A11 and HO-1 expression.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…